KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Guardant Health (GH) EBITDA: 2017-2025

Historic EBITDA for Guardant Health (GH) over the last 8 years, with Sep 2025 value amounting to -$99.0 million.

  • Guardant Health's EBITDA rose 15.63% to -$99.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year increase of 14.12%. This contributed to the annual value of -$443.6 million for FY2024, which is 21.45% up from last year.
  • Per Guardant Health's latest filing, its EBITDA stood at -$99.0 million for Q3 2025, which was up 6.98% from -$106.4 million recorded in Q2 2025.
  • Guardant Health's EBITDA's 5-year high stood at -$97.6 million during Q2 2021, with a 5-year trough of -$197.5 million in Q4 2023.
  • Over the past 3 years, Guardant Health's median EBITDA value was -$113.5 million (recorded in 2023), while the average stood at -$120.4 million.
  • In the last 5 years, Guardant Health's EBITDA tumbled by 208.96% in 2021 and then surged by 36.22% in 2024.
  • Over the past 5 years, Guardant Health's EBITDA (Quarterly) stood at -$98.2 million in 2021, then slumped by 48.79% to -$146.1 million in 2022, then tumbled by 35.17% to -$197.5 million in 2023, then surged by 36.22% to -$126.0 million in 2024, then increased by 15.63% to -$99.0 million in 2025.
  • Its EBITDA stands at -$99.0 million for Q3 2025, versus -$106.4 million for Q2 2025 and -$111.0 million for Q1 2025.